

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

[Find a Physician](#) [Find a Program](#) [Find a Treatment](#)  
[Learn About Cancer & Treatment](#)



## ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

## FOR THE MEDIA



**David R. Jones, MD**

**Thoracic Surgeon** ([#about-me](#))



## Areas of Expertise

### Conditions I Treat

- Lung cancer
- Esophageal cancers and conditions
- Germ cell tumors

## My Specialties

- Minimally invasive surgery
- Video-assisted thoracic surgery (VATS)
- Endobronchial ultrasound (EBUS)

[View more expertise \(#about\\_specialties\)](#)



[Dr. Jones's Office Information \(#contact-and-location\)](#)



Languages: English

## Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

[Call 646-497-9163](#)

[Make an appointment](#)

## Get to Know Me

I am a thoracic surgeon who has been caring for people with cancers of the chest for more than 24 years. I have expertise diagnosing and treating [lung cancer](#) , [esophageal cancer](#) , tumors of the mediastinum ([thymus](#) gland and germ cell tumors), and tumors that have metastasized (spread) to the lung from other parts of the body.

In addition to serving as Chief of Thoracic Surgery, I am the Co-Director of the Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center and Executive Vice-Chair for the Department of Surgery.

Read more +

[What I Do at MSK](#)

I'm a thoracic (thor-A-sik) surgeon. This is a doctor with special training in surgery for the chest, lungs, airway, esophagus (swallowing tube), and thymus. They're also known as a chest surgeon.

- Chief, Thoracic Service, Department of Surgery
- Co-Director, Druckenmiller Center for Lung Cancer Research
- Fiona and Stanley Druckenmiller Chair in Lung Cancer
- Executive Vice-Chair, Department of Surgery

## Areas of Expertise

### Conditions I Treat

- Lung cancer
- Esophageal cancers and conditions
- Germ cell tumors
- Thymic carcinoma
- Lung metastases
- Mediastinal tumors
- Tracheal and bronchial cancers and conditions

### My Specialties

- Minimally invasive surgery
- Video-assisted thoracic surgery (VATS)
- Endobronchial ultrasound (EBUS)

## Education & Honors

### Education

- MD, West Virginia University

### Residencies

- General Surgery - West Virginia University

- Thoracic Surgery - University of North Carolina

## Fellowships

- Molecular Oncology - University of North Carolina

## Board Certifications

- General Surgery
- Thoracic Surgery

## Awards and Honors

- Castle Connolly: America's Top Doctor (2026)
- Castle Connolly: America's Top Doctor (2025)
- President, American Association for Thoracic Surgery (2024)
- Castle Connolly: America's Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2006-2023)
- National Cancer Institute, Board of Scientific Counselors (2019-2024)
- President, Southern Thoracic Surgical Association (2016-2017)
- Chair, Tumor Progression Metastasis Study Section, National Cancer Institute (2014-2016)
- West Virginia University School of Medicine Distinguished Alumnus (2013)
- American Association for Cancer Research Career Development Award for Translational Lung Cancer Research (2001)

## Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176) .

# Make an Appointment

## New Patients

Scheduling an appointment is easy. Click or call [646-497-9163](tel:646-497-9163) — we're available 24 hours a day, 7 days a week

[Make an Appointment](#)

## Current Patients

Request an appointment by calling your Care Team or messaging them in [MSK MyChart](#).

# Contact and Location

## Office Phone

 [212-639-6428](tel:212-639-6428)

## Location

 New York, NY

[David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center](#)

 530 East 74th Street  
New York, NY 10021  
[Get Directions](#)

[Memorial Sloan Kettering Cancer Center](#)

 1275 York Avenue  
New York, NY 10065

[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .

## Clinical Trials

- Clinical Trials Investigated by Dr. Jones
- [A Phase 3 Study of Rilvegostomig Alone or With Dato-DXd Versus Standard Treatment for Stage 1 Lung Cancer With High-Risk Features](#)
- Clinical Trials Co-Investigated by Dr. Jones
- [A Study of Tumor-Treating Fields \(TTFields\) in People with Lung Adenocarcinoma](#)



### Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

## Research and Publications

[View Dr. Jones's Lab](#)

Kiankhooy A, Taylor MD, LaPar D, Isbell JM, Kozower BD, Lau CL, Jones DR. Predictors of early recurrence for node-negative T1-T2b non-small cell lung cancer. *Ann Thorac Surgery* 2014;98(4):1175-83.

Liu Y, Amin EB, Mayo MW, Chudgar NP, Bucciarelli PR, Kadota K, Adusumilli PS, Jones DR. CK2 $\alpha$ ' drives lung cancer metastasis by targeting BRMS1 nuclear export and degradation. *Cancer Res* 2016;76:2675-86.

Chudgar NP, Brennan MF, Munhoz RR, Bucciarelli PR, Tan KS, D'Angelo SP, Bains MS, Bott M, Huang J, Park BP, Rusch VR, Adusumilli PS, Jones DR. Pulmonary metastasectomy with curative intent for soft tissue sarcoma. *J Thorac Cardiovasc Surg* 2017;154:319-30.

Jones DR. Bending the curve: the importance of expertise. *Ann Thorac Surg* 2018;103:1287-93.

Brandt WS, Yan W, Tan KS, Bains MS, Park BJ, Adusumilli PS, Huang J, Bott MJ, Rusch VW, Molena D, Isbell JM, Sihag S, Chaft JE, Kris MG, Jones DR. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis. *J Thorac Cardiovasc Surg* 2019;157(2):743-753.

[Read more +](#)

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

David R. Jones discloses the following relationships and financial interests:

- American Association for Thoracic Surgery  
Fiduciary Role / Position
- AstraZeneca  
Professional Services and Activities
- Merck & Co Inc.  
Professional Services and Activities (Uncompensated)
- National Cancer Institute  
Professional Services and Activities (Uncompensated)

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center